Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239130 | 1.00 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2225858 | 1.00 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1478166 | 0.95 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1478184 | 0.95 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL82116 | 0.95 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1398934 | 0.90 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL29755212 | 0.90 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5069216 | 0.90 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL31638601 | 0.87 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2636790 | 0.87 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724782-A | Vildagliptin Synthesis method of intermediate | 河北合佳医药科技集团股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-217909224-U | Purification device for Boc-prolinamide production | 富乐马鸿凯（大连）医药有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-217368143-U | Boc-prolinamide production is with mixing device | 富乐马鸿凯（大连）医药有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-217357896-U | A drying device for Boc-prolinamide preparation | 富乐马鸿凯（大连）医药有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114163372-A | Continuous preparation method of vildagliptin key intermediate | 河北合佳医药科技集团股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE LTD (SG) | 2025-12-25 | — | — | US | disclosed |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
| US-5591758-A | ANGINA PECTORIS TREATMENT | LABORATOIRES HOECHST, SA (FR) | 1997-01-07 | — | — | US | disclosed |
| US-5244884-A | Tripeptide | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0202048-B1 | CARBAPENEM DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4771046-A | ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1988-09-13 | — | — | US | disclosed |
| EP-0202048-A1 | Carbapenem derivatives, their preparation, and pharmaceutical compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | HSD17B10 2720/4885SMN1; SMN2 737/4885NPC1 1158/4885 |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | PKMYT1, PKN1, PRKCB | HSD17B10 2211/4885SMN1; SMN2 3904/4885NPC1 190/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | HSD17B10 804/4885SMN1; SMN2 4493/4885NPC1 1617/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | HSD17B10 3641/4885SMN1; SMN2 2048/4885NPC1 1662/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | HSD17B10 4006/4885SMN1; SMN2 2248/4885NPC1 1614/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | HSD17B10 4090/4885SMN1; SMN2 903/4885NPC1 3337/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | HSD17B10 3177/4885SMN1; SMN2 3112/4885NPC1 3621/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | HSD17B10 32/4885SMN1; SMN2 4532/4885NPC1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.